Company intelligence / Profile preview
Abata Therapeutics
Cambridge, Massachusetts, United Statesabatatx.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Phase 1
01
Overview
Abata Therapeutics has initiated its first clinical study in 2024 and received FDA Fast Track Designation for ABA-101 for the treatment of Progressive Multiple Sclerosis. The company is also completing late pre-clinical studies for ABA-201 for Type 1 Diabetes with clinical studies expected to begin in 2025.
- Therapeutic areas
- EndocrinologyImmunologyNeurology
- Modalities
- Regulatory T cell (Treg) therapiesCell therapyAutologous cell therapyTCR-engineered Treg cell therapies
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on Abata Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Abata Therapeutics.